156 related articles for article (PubMed ID: 38052910)
21. Dasatinib sensitizes KRAS mutant colorectal tumors to cetuximab.
Dunn EF; Iida M; Myers RA; Campbell DA; Hintz KA; Armstrong EA; Li C; Wheeler DL
Oncogene; 2011 Feb; 30(5):561-74. PubMed ID: 20956938
[TBL] [Abstract][Full Text] [Related]
22. The Prognostic Impact of KRAS G12C Mutation in Patients with Metastatic Colorectal Cancer: A Multicenter Retrospective Observational Study.
Chida K; Kotani D; Masuishi T; Kawakami T; Kawamoto Y; Kato K; Fushiki K; Sawada K; Kumanishi R; Shirasu H; Matsubara Y; Yuki S; Komatsu Y; Yamazaki K; Yoshino T
Oncologist; 2021 Oct; 26(10):845-853. PubMed ID: 34232546
[TBL] [Abstract][Full Text] [Related]
23. Cetuximab continuation after first progression in metastatic colorectal cancer (CAPRI-GOIM): a randomized phase II trial of FOLFOX plus cetuximab versus FOLFOX.
Ciardiello F; Normanno N; Martinelli E; Troiani T; Pisconti S; Cardone C; Nappi A; Bordonaro AR; Rachiglio M; Lambiase M; Latiano TP; Modoni G; Cordio S; Giuliani F; Biglietto M; Montesarchio V; Barone C; Tonini G; Cinieri S; Febbraro A; Rizzi D; De Vita F; Orditura M; Colucci G; Maiello E;
Ann Oncol; 2016 Jun; 27(6):1055-1061. PubMed ID: 27002107
[TBL] [Abstract][Full Text] [Related]
24. Andrographolide sensitizes KRAS-mutant colorectal cancer cells to cetuximab by inhibiting the EGFR/AKT and PDGFRβ/AKT signaling pathways.
Liu YF; Feng ZQ; Chu TH; Yi B; Liu J; Yu H; Xue J; Wang YJ; Zhang CZ
Phytomedicine; 2024 Apr; 126():155462. PubMed ID: 38394734
[TBL] [Abstract][Full Text] [Related]
25. KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab.
Lièvre A; Bachet JB; Boige V; Cayre A; Le Corre D; Buc E; Ychou M; Bouché O; Landi B; Louvet C; André T; Bibeau F; Diebold MD; Rougier P; Ducreux M; Tomasic G; Emile JF; Penault-Llorca F; Laurent-Puig P
J Clin Oncol; 2008 Jan; 26(3):374-9. PubMed ID: 18202412
[TBL] [Abstract][Full Text] [Related]
26. Randomised phase II study of panitumumab plus irinotecan versus cetuximab plus irinotecan in patients with KRAS wild-type metastatic colorectal cancer refractory to fluoropyrimidine, irinotecan and oxaliplatin (WJOG 6510G).
Sakai D; Taniguchi H; Sugimoto N; Tamura T; Nishina T; Hara H; Esaki T; Denda T; Sakamoto T; Okuda H; Satoh T; Tsushima T; Makiyama A; Tsuda T; Hosokawa A; Kuramochi H; Tokunaga S; Moriwaki T; Yasui H; Ishida H; Tsuji A; Otsu S; Shimokawa H; Baba E; Sato M; Matsumoto S; Ozaki Y; Shinozaki K; Tamagawa H; Goto M; Kadowaki S; Fujii H; Koh Y; Yamazaki K; Hironaka S; Kishimoto J; Boku N; Hyodo I; Muro K
Eur J Cancer; 2020 Aug; 135():11-21. PubMed ID: 32526634
[TBL] [Abstract][Full Text] [Related]
27. Rechallenge for Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer With Acquired Resistance to First-line Cetuximab and Irinotecan: A Phase 2 Single-Arm Clinical Trial.
Cremolini C; Rossini D; Dell'Aquila E; Lonardi S; Conca E; Del Re M; Busico A; Pietrantonio F; Danesi R; Aprile G; Tamburini E; Barone C; Masi G; Pantano F; Pucci F; Corsi DC; Pella N; Bergamo F; Rofi E; Barbara C; Falcone A; Santini D
JAMA Oncol; 2019 Mar; 5(3):343-350. PubMed ID: 30476968
[TBL] [Abstract][Full Text] [Related]
28. Epidermal growth factor receptor (EGFR) inhibitors for metastatic colorectal cancer.
Chan DLH; Segelov E; Wong RS; Smith A; Herbertson RA; Li BT; Tebbutt N; Price T; Pavlakis N
Cochrane Database Syst Rev; 2017 Jun; 6(6):CD007047. PubMed ID: 28654140
[TBL] [Abstract][Full Text] [Related]
29. Divarasib in the Evolving Landscape of KRAS G12C Inhibitors for NSCLC.
Brazel D; Nagasaka M
Target Oncol; 2024 May; 19(3):297-301. PubMed ID: 38739329
[TBL] [Abstract][Full Text] [Related]
30. Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer.
Misale S; Yaeger R; Hobor S; Scala E; Janakiraman M; Liska D; Valtorta E; Schiavo R; Buscarino M; Siravegna G; Bencardino K; Cercek A; Chen CT; Veronese S; Zanon C; Sartore-Bianchi A; Gambacorta M; Gallicchio M; Vakiani E; Boscaro V; Medico E; Weiser M; Siena S; Di Nicolantonio F; Solit D; Bardelli A
Nature; 2012 Jun; 486(7404):532-6. PubMed ID: 22722830
[TBL] [Abstract][Full Text] [Related]
31. A Phase II Study of Sorafenib Combined With Cetuximab in EGFR-Expressing, KRAS-Mutated Metastatic Colorectal Cancer.
Do K; Cao L; Kang Z; Turkbey B; Lindenberg ML; Larkins E; Holkova B; Steinberg SM; Raffeld M; Peer CJ; Figg WD; Eugeni M; Jacobs P; Choyke P; Wright JJ; Doroshow JH; Kummar S
Clin Colorectal Cancer; 2015 Sep; 14(3):154-61. PubMed ID: 25861837
[TBL] [Abstract][Full Text] [Related]
32. Efficacious Combination Drug Treatment for Colorectal Cancer That Overcomes Resistance to KRAS G12C Inhibitors.
Matsubara H; Miyoshi H; Kakizaki F; Morimoto T; Kawada K; Yamamoto T; Obama K; Sakai Y; Taketo MM
Mol Cancer Ther; 2023 Apr; 22(4):529-538. PubMed ID: 36780229
[TBL] [Abstract][Full Text] [Related]
33. Safety and efficacy of the addition of simvastatin to cetuximab in previously treated KRAS mutant metastatic colorectal cancer patients.
Baas JM; Krens LL; ten Tije AJ; Erdkamp F; van Wezel T; Morreau H; Gelderblom H; Guchelaar HJ
Invest New Drugs; 2015 Dec; 33(6):1242-7. PubMed ID: 26386973
[TBL] [Abstract][Full Text] [Related]
34. First-in-Human Phase I/IB Dose-Finding Study of Adagrasib (MRTX849) in Patients With Advanced
Ou SI; Jänne PA; Leal TA; Rybkin II; Sabari JK; Barve MA; Bazhenova L; Johnson ML; Velastegui KL; Cilliers C; Christensen JG; Yan X; Chao RC; Papadopoulos KP
J Clin Oncol; 2022 Aug; 40(23):2530-2538. PubMed ID: 35167329
[TBL] [Abstract][Full Text] [Related]
35. KRAS G12C Metastatic Colorectal Cancer: Specific Features of a New Emerging Target Population.
Schirripa M; Nappo F; Cremolini C; Salvatore L; Rossini D; Bensi M; Businello G; Pietrantonio F; Randon G; Fucà G; Boccaccino A; Bergamo F; Lonardi S; Dei Tos AP; Fassan M; Loupakis F
Clin Colorectal Cancer; 2020 Sep; 19(3):219-225. PubMed ID: 32605718
[TBL] [Abstract][Full Text] [Related]
36. Randomized, phase II study of the insulin-like growth factor-1 receptor inhibitor IMC-A12, with or without cetuximab, in patients with cetuximab- or panitumumab-refractory metastatic colorectal cancer.
Reidy DL; Vakiani E; Fakih MG; Saif MW; Hecht JR; Goodman-Davis N; Hollywood E; Shia J; Schwartz J; Chandrawansa K; Dontabhaktuni A; Youssoufian H; Solit DB; Saltz LB
J Clin Oncol; 2010 Sep; 28(27):4240-6. PubMed ID: 20713879
[TBL] [Abstract][Full Text] [Related]
37. Panitumumab in patients with KRAS wild-type colorectal cancer after progression on cetuximab.
Wadlow RC; Hezel AF; Abrams TA; Blaszkowsky LS; Fuchs CS; Kulke MH; Kwak EL; Meyerhardt JA; Ryan DP; Szymonifka J; Wolpin BM; Zhu AX; Clark JW
Oncologist; 2012; 17(1):14. PubMed ID: 22210091
[TBL] [Abstract][Full Text] [Related]
38. Cetuximab plus FOLFOX-4 in untreated patients with advanced colorectal cancer: a Gruppo Oncologico dell'Italia Meridionale Multicenter phase II study.
Colucci G; Giuliani F; Garufi C; Mattioli R; Manzione L; Russo A; Lopez M; Parrella P; Tommasi S; Copetti M; Daniele B; Pisconti S; Tuveri G; Silvestris N; Maiello E
Oncology; 2010; 79(5-6):415-22. PubMed ID: 21474966
[TBL] [Abstract][Full Text] [Related]
39. Effect of simvastatin on cetuximab resistance in human colorectal cancer with KRAS mutations.
Lee J; Lee I; Han B; Park JO; Jang J; Park C; Kang WK
J Natl Cancer Inst; 2011 Apr; 103(8):674-88. PubMed ID: 21398618
[TBL] [Abstract][Full Text] [Related]
40. MicroRNA-425-5p Expression Affects BRAF/RAS/MAPK Pathways In Colorectal Cancers.
Angius A; Pira G; Scanu AM; Uva P; Sotgiu G; Saderi L; Manca A; Serra C; Uleri E; Piu C; Caocci M; Ibba G; Zinellu A; Cesaraccio MR; Sanges F; Muroni MR; Dolei A; Cossu-Rocca P; De Miglio MR
Int J Med Sci; 2019; 16(11):1480-1491. PubMed ID: 31673240
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]